Two cellular medicines for multiple myeloma were associated with an increased risk of early death in clinical testing, raising questions about whether they should be earlier in a patient’s disease, Food and Drug Administration scientists wrote in a briefing document published on Wednesday.
On Friday, the FDA will convene a panel of experts to discuss whether the two cell therapies — Legend Biotech and Johnson & Johnson’s Carvykti, and Bristol Myers Squibb’s Abecma — should be used as early as after a patient’s first relapse.
